Other name:Rucaparib intermediates,8-fluoro-1345-tetrahydro-2-[4-[(methylamino)methyl]phenyl]
Rucaparib is a PARP inhibitor used as an anti-cancer agent. Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1). It was discovered as part of a collaboration between scientists working at the Northern Institute of Cancer Research and Medical School of Newcastle University and Agouron Pharmaceuticals in San Diego, California. It is being developed by Clovis Oncology.
In December 2016, the U.S. FDA granted an accelerated approval for use in cases of pretreated advanced ovarian cancer.
In Europe it was designated as an orphan medicinal product on 10 October 2012. On 22 March 2018 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation, intended for the treatment of relapsed or progressive ovarian cancer.